Management of concomitant medication interactions

The manuals converge on the need for a careful review of concomitant medication and substance use before psychedelic dosing, with ongoing attention to safety and study integrity. Across the extracts, they consistently flag serotonergic agents as a key concern, alongside other prohibited or higher risk classes such as stimulants, antidepressants, antipsychotics, MAOIs, lithium, anticonvulsants, and addiction treatment medications. Several sources also link this review to practical steps such as washout periods, tapering when clinically appropriate, and consultation with prescribers or a medical monitor when medication compatibility is uncertain. They also agree that interaction management is not limited to prescription medicines. The manuals mention OTC products, herbal supplements, vitamins, minerals, and other nonprescription agents as part of the review, and they treat concurrent substance use as relevant to adverse event risk or confounding. Serotonin syndrome or serotonin toxicity appears repeatedly as a specific safety signal, while one source adds concern about QTc prolongation with ibogaine and another highlights cardiovascular, psychosis, mania, pregnancy, and substance use exclusions in the psilocybin bipolar protocol. The main differences are in emphasis and the interaction profile each manual foregrounds.